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and oxcarbazepine.4
When a clear sequence of events is
available, as in the present case, the risk of
antipsychotics combinedwith carbamazepine/
oxcarbazepine leading to SIADH or poly-
dipsia19 should be seriously evaluated up-
front, especially in a patient with genetic
epilepsy who is at increased risk due to a
supratherapeutic carbamazepine therapy. To
prevent electrolyte imbalances, a cheap and
feasible strategy comprises routine blood
examinations, therapeutic drug monitor-
ing, and the monitoring of patients' water
intake because polydipsia may be an im-
portant pathological marker. This grants
the opportunity to detect subtle electro-
lyte changes that may otherwise go unno-
ticed until they have a clinically relevant
impact. Proper monitoring should be al-
ways performed as a precaution because
subclinical hyponatremia may also reduce
neuropsychological performances.20
The present case is an example of how
2 drugs with a low-risk potential synergized
to produce an adverse reaction. The risk of
developing an ADR in this patient went un-
noticed; because she never displayed poly-
dipsia, detection of the ADR was virtually
impossible without an accidental blood
examination. Proper drug monitoring and
knowledge of drug-specific risks of ADRs
may prevent seizure precipitation due to elec-
trolyte imbalances and should be encouraged
as part of an optimal clinical practice.
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Interaction Between
Risperidone, Venlafaxine,
and Metronidazole
An Unknown Thread
To the Editors:W hen metronidazole (MET) wascoprescribed to an ongoing phar-
macological treatment, elevated plasma
concentrations have been reported for a
number of cytochrome CYP3A substrates
including amiodarone, carbamazepine, cy-
closporine, and others. The clinical signifi-
cance of drug-drug interactions (DDIs) has
been illustrated mostly by case reports.1,2
However, pharmacokinetic evidence does
not support an inhibiting effect of MET on
CYP3A4/5 activity.3 Alternatively, dose-
dependent pharmacokinetic patternsmay of-
fer explanatory models for the discrepancy
between case reports and in vivo studies.4
In vitro findings imply an inhibiting effect
ofMETonCYP2C9, but not onCYP2D6.5,6
However, the mechanism by which MET
alters the disposition of different drugs
including tacrolimus, amiodarone, cyclo-
sporine, carbamazepine, and quinidine3
remains unclear so far; it might also be a
result of its influence on transport pro-
teins such as p-glycoprotein, although
data do not support an inhibiting effect
on p-glycoprotein hitherto.7,8 Hence,Wolters Kluwer Health, Inc. All rights reserved.
served.
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drugs have to be further elucidated be-
cause they may be the result of various
processes including alterations in absorp-
tion, distribution, metabolism, and excre-
tion of the affected drug. In addition,
inflammatory conditions may be associ-
ated with CYP inhibition9 and particularly
with an inhibition of risperidone (RIS) me-
tabolism.10,11 Researchers suggested that
the underlying mechanism might include
CYP3A4, glucuronosyltransferases, or drug
efflux transporters.10 In this regard, thera-
peutic drug monitoring (TDM) can be used
to optimize patient-oriented pharmacother-
apy helping to disentangle DDIs in clinical
settings. Therefore, we report a clinically
interesting case in which the addition of
MET to an ongoing treatment with RIS
and venlafaxine (VEN) led to an unexpected
increase of the serum levels and a change in
the relation between the parent compound
and the metabolites (altering the so-called
metabolic ratio) of both psychotropic drugs.CASE REPORT
Mrs L is an 81-year-old inpatient diagnosed
with a recurrent major depressive disorder
with psychotic symptoms (ICD-10: F33.3)
including delusion of poisoning. She was
hospitalized in the Department of Psychia-
try, Psychotherapy and Psychosomatics,
University Hospital of Aachen, Germany,
and was initially treated with nortriptyline
75 mg and RIS up to 2 mg. This was theTABLE 1. Serum Concentrations of RIS and I
as Trough Levels
Day (Start of METon Day 0)
CRP (mg/L)
Albumin (g/dL)
Total protein (g/dL)
Blood creatinine (mg/L)
Creatinine clearance (mL/min/1.73 m2)
DD RIS (mg)
RIS (ng/mL)
9-OH-RIS (ng/mL)
RIS + 9-OH-RIS (ng/mL)
Ratio 9-OH-RIS/RIS
DDVEN (mg)
VEN (ng/mL)
ODV (ng/mL)
VEN + ODV (ng/mL)
Ratio, ODV/VEN
Because of the short interval between TDMmeas
could not be established.
np indicates not performed.
© 2016 Wolters Kluwer Health, Inc. All rights reser
Copyright therapeutic regimen at the time of admis-
sion. Because of a lack of response in the
outpatient setting, VENwas started in daily
dosages up to 187.5 mg, RIS dosage was
increased up to 4 mg, and nortriptyline
was stopped. The patient had been already
under this therapeutic regimen for a week
when shewas diagnosed with a nosocomial
infection of the urinary tract. Cefuroxime
was added for an antimicrobial therapy.
Hereafter, a Clostridium difficile–associated
diarrhea occurred, and an antimicrobial ther-
apywithMET in a daily dosage of 1,200mg
(in 400 mg tablets) was initiated, and rou-
tine examinations including TDM were
performed regularly. The clinical condition
was marked by exsiccosis and general ex-
haustion on the day when METwas started.
The laboratory revealed a C-reactive pro-
tein (CRP) enhancement up to 70.2 mg/mL
(reference range, <5 mg/mL) but normal
leucocytes. Furthermore, starting from initially
normal serum sodium levels, a hyponatremia
with a level of 129 mmol/L (reference range,
136–145 mmol/L) occurred 2 days after the
MET therapy initiation, whereas no changes
in electrocardiogram results were observed
(QTC 441 milliseconds). At this point, renal
function parameters were normal.Twoweeks before the start of the anti-
microbial treatment, the serum level for the
so-called activemoiety (AM) (sumofRIS +
9-hydroxyrisperidone [9-OH-RIS]) was
77.9 ng/mL and higher as the therapeutic
reference range of 20 to 60 ng/mL.12 None-
theless, the daily dosage of 4 mg remainedts Metabolite 9-OH-RIS as well as Serum Conc
Concomitan
Before Day 5 Day 6
42.0 42.3 32.1
np np np
np np np
7.6 4.7 6.2
73.8 92.9 84.8
4 4 4
2.5 17 28
75.4 173 197
77.9 190 225
30.16 10.18 7.04
75.0 187.5 187.5
np 496 446
np 886 803
np 1382 1249
np 1.79 1.80
ures and the long half-life of RIS and particular 9-OH
ved.
© 2016 Wolters Kluwer Health, Inc. All rights runchanged. At this moment, it had been
only 3 days after initiation of VEN therapy
and daily dosage was low; thereby, TDM
did not include VEN. After starting the
MET treatment (on day 0), serum levels
of the AM were raised up to 225 ng/mL
(Table 1) and exceeded the upper thresh-
old of the therapeutic reference range nearly
fourfold. Serum concentrations of VEN
and O-desmethylvenlafaxine (ODV) were
found to be unusually high after starting
MET. The AM (VEN + ODV) was found
to be 1382 ng/mL and exceeded the upper
threshold of the therapeutic reference range
for VEN (100–400 ng/mL) more than
threefold.12 Although serum levels for both
psychotropic drugs were very high, no
signs of intoxication or severe adverse ef-
fects could be observed. Only the low blood
pressure and intermittent nonvertiginous
dizziness, associated with headache, were
clinically evident. Revealing the decrease
in sodium serum levels and the high drug
concentrations justified an adjustment of
the therapeutic regimen, and the applied
daily dosages were reduced. However, the
patient was transferred to an internal ward
because of continuing diarrhea. One week
later, she was released home with the dis-
charge diagnoses of clostridial enteritis and
urinary tract infection caused by Pseudomo-
nas aeruginosa. The discharge therapeutic
regimen consisted of RIS 4 mg and VEN
75 mg. Aside from the psychopharmacolog-
ical treatment, the patient received an antimi-
crobial therapy with vancomycin 750 mgentrations of VEN and Its Metabolite ODV
t Treatment With MET
Day 10 Day 12 Day 17
21.0 18.3 60.4
np np 1.9
np 4.1 4.1
4.3 4.1 5.3
95.7 97.2 89.3
4 2 2
18.9 39.6 8.3
171 137 88.4
189.9 176.6 96.7
9.05 3.46 10.65
187.5 150.0 75.0
143 160 224
457 470 282.7
600 630 506.7
3.20 2.94 1.26
-RIS, steady-state conditions (>5 half-life times)
www.psychopharmacology.com 731
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had been already stopped when the patient
was transferred to the internal ward.DISCUSSION
The primary pathway of RIS metabolism is
a CYP2D6-catalyzed 9-hydroxylation, and
the main active metabolite is 9-OH-RIS.
Furthermore, in vitro findings have revealed
that CYP3A4 and CYP3A5might be also in-
volved in the metabolism of RIS.13 Risperi-
done and 9-OH-RIS exhibit differences in
5-HT2A/D2 (serotonin/dopamine) binding
ratios, show differences in plasma-protein
binding (90% vs 74%) and in terminal
half-life time (3 hours for RIS vs 23 hours
for 9-OH-RIS). For RIS, 2 TDM measures
have received particular attention14; the ratio
RIS/9-OH-RIS is considered as a reliable
measure of CYP2D6 metabolic activity,
and the AM (RIS + 9-OH-RIS) divided
by the RIS dosage (total concentration-
by-dose ratio in [ng/mL]/[mg/d]) is consid-
ered to sufficiently reflect the total clearance
of RIS. If the latter is increased in the
absence of an increase in RIS/9-OH-RIS,
it may be a sign of CYP3A4 inhibition.
Venlafaxine is principally metabolized not
only by CYP2D6 to ODV, its major active
metabolite, but also by CYP3A4 to the in-
active metabolite N-desmethylvenlafaxine,
and, to some degree,CYP2C19 andCYP2C9
play a role in the metabolism of VEN too.
When comparing VEN with other antide-
pressants, it is reported to show a low pro-
tein binding (27% for VEN and 30% for
ODV).15 Of clinical interest are the differ-
ences between VEN and ODV regarding
their half-life (5 and 11 hours) as well as re-
nal excretion (5% and 30%).16 The ratio
ODV to VEN provides valuable informa-
tion for the metabolizer status,17 whereas
the total ODV + VEN concentration divided
by VEN dosage ([{VEN + ODV}/D] in [ng/
mL]/[mg/d]) should provide a reasonable
measure of total VEN clearance12 as the
so-called dose-adjusted plasma or serum
concentration. There is a previously de-
scribed pharmacokinetic interaction be-
tween VEN and RIS via CYP2D6 because
VEN is a weak inhibitor of 2D6 leading
to higher concentrations of RIS and to a de-
crease in renal elimination of 9-OH-RIS.18
The metabolism of MET is indepen-
dent from CYP2D6 activity,19 and the main
metabolic pathway involves CYP2A6. No
pharmacokinetic interactions between MET
and RIS orMETand VEN are previously de-
scribed. Of specific interest is the spectacular
increase in blood levels and particularly active
metabolites of both psychotropic drugs; this
implies an effect ofMETon both drugs rather
than a cascade of pharmacokinetic changes.
However, pharmacokinetic interactions via732 www.psychopharmacology.com
Copyright ©the cytochrome system do not sufficiently
account for the increase of drug concentra-
tions of RIS, 9-OH-RIS, VEN, and ODV
after the addition of MET. Moreover, there
were no hints of renal impairment. There-
fore, it remains unclear why, in the case of
9-OH-RIS and ODV, the patient was not
able to eliminate the metabolites. It might
be seen as a complex pharmacokinetic inter-
action and/or the consequence of the inflam-
matory condition. Nevertheless, in our case,
an inhibitory effect of inflammation is not
clearly demonstrated because the temporal
course of CRP values did not match the
course of the drugs' serum levels. Knowl-
edge of CYP2D6 and CYP2C19 genotypes
would undoubtedly shed light on the mech-
anism underpinning the interaction reported
here. However, genetic tests of CYP activity
for polymorphic cytochrome enzymes
are still not established in clinical routine,
and this option was not available in our
case hampering a better understanding
of this evidence.
Our case underscores the usefulness
of TDM for treatment optimization and
improvement of patients' safety. Luckily,
except orthostatic hypotension and dizzi-
ness, no other clinically relevant adverse
effects could be observed. The mentioned
undesirable effects partly subsided after
reducing the daily dosage of RIS and
VEN. Our case report highlights the bene-
fits of TDM application in clinical routine
as an alarm for individual abnormalities
such as DDIs essentially helping to prevent
negative outcomes.
AUTHOR DISCLOSURE
INFORMATION
Gerhard Gründer has served as a
consultant for Boehringer Ingelheim
(Ingelheim, Germany), Cheplapharm
(Greifswald, Germany), Eli Lilly (India-
napolis, Ind), Lundbeck (Copenhagen,
Denmark), Ono Pharmaceuticals (Osaka,
Japan), Roche (Basel, Switzerland), Servier
(Paris, France), and Takeda (Osaka, Japan).
He has served on the speakers' bureau
of Eli Lilly, Gedeon Richter (Budapest,
Ungarn), Janssen Cilag (Neuss, Germany),
Lundbeck, Roche, Servier, and Trommsdorf
(Aachen, Germany). He has received grant
support from Boehringer Ingelheim and
Roche. He is cofounder of Pharma Im-
age GmbH (Düsseldorf, Germany) and
Brainfoods UG (Selfkant, Germany). The
other authors declare no conflicts of interest.
Jana Hovancakova, MD
Department of Psychiatry
Psychotherapy and Psychosomatics
RWTH Aachen University
Aachen, Germany
and JARA –
Translational Brain Medicine© 2016
 2016 Wolters Kluwer Health, Inc. All rights reGeorgios Schoretsanitis, MD
Department of Psychiatry
Psychotherapy and Psychosomatics
RWTH Aachen University
Aachen, Germany
and JARA –
Translational Brain Medicine
and Translational Research Center
University Hospital of Psychiatry
Bern, Switzerland
george.schor@gmail.com
Michael Grözinger, MD
Gerhard Gründer, MD
Michael Paulzen, MD
Department of Psychiatry
Psychotherapy and Psychosomatics
RWTH Aachen University
Aachen, Germany
and JARA –
Translational Brain Medicine
REFERENCES
1. Page RL 2nd, Klem PM, Rogers C. Potential
elevation of tacrolimus trough concentrations
with concomitant metronidazole therapy.
Ann Pharmacother. 2005;39:1109–1113.
2. Kounas SP, Letsas KP, Sideris A, et al. QT
interval prolongation and torsades de pointes
due to a coadministration of metronidazole and
amiodarone. Pacing Clin Electrophysiol. 2005;
28:472–473.
3. Roedler R, Neuhauser MM, Penzak SR. Does
metronidazole Interact with CYP3A substrates
by inhibiting their metabolism through this
metabolic pathway? Or should other
mechanisms be considered?
Ann Pharmacother. 2007;41:653–658.
4. Dilger K, Fux R, Rock D, et al. Effect of
high-dose metronidazole on pharmacokinetics
of oral budesonide and vice versa: a double
drug interaction study. J Clin Pharmacol. 2007;
47:1532–1539.
5. Obach RS, Walsky RL, Venkatakrishnan K,
et al. The utility of in vitro cytochrome P450
inhibition data in the prediction of drug-drug
interactions. J Pharmacol Exp Ther. 2006;316:
336–348.
6. Levy RH. Cytochrome P450 isozymes and
antiepileptic drug interactions. Epilepsia. 1995;
36(Suppl 5):8–13.
7. Kim KA, Park JY. Effect of metronidazole on
the pharmacokinetics of fexofenadine, a
P-glycoprotein substrate, in healthy male
volunteers. Eur J Clin Pharmacol. 2010;66:
721–725.
8. Wang JS, Backman JT, Kivistö KT, et al. Effects
of metronidazole on midazolam metabolism in
vitro and in vivo. Eur J Clin Pharmacol. 2000;
56:555–559.
9. Shah RR, Smith RL. Inflammation-induced
phenoconversion of polymorphic drug
metabolizing enzymes: hypothesis with
implications for personalized medicine. Drug
Metab Dispos. 2015;43:400–410.Wolters Kluwer Health, Inc. All rights reserved.
served.
Journal of Clinical Psychopharmacology • Volume 36, Number 6, December 2016 Letters to the Editors10. Hefner G, Falter T, Bruns K, et al. Elevated
risperidone serum concentrations during acute
inflammation, two cases. Int J Psychiatry Med.
2015;50:335–344.
11. Hefner G, Shams ME, Unterecker S, et al.
Inflammation and psychotropic drugs: the
relationship between C-reactive protein and
antipsychotic drug levels.Psychopharmacology
(Berl). 2016;233:1695–1705.
12. Hiemke C, Baumann P, Bergemann N, et al.
AGNP consensus guidelines for therapeutic
drug monitoring in psychiatry: update 2011.
Pharmacopsychiatry. 2011;44:195–235.
13. Fang J, Bourin M, Baker GB. Metabolism of
risperidone to 9-hydroxyrisperidone by human
cytochromes P450 2D6 and 3A4. Naunyn
Schmiedebergs Arch Pharmacol. 1999;359:
147–151.
14. Spina E, de Leon J. Clinical applications of
CYP genotyping in psychiatry. J Neural Transm
(Vienna). 2015;122:5–28.
15. Preskorn SH. Pharmacokinetics of
antidepressants: why and how they are relevant
to treatment. J Clin Psychiatry. 1993;54(Suppl):
14–34 discussion 55-16.
16. Klamerus KJ, Maloney K, Rudolph RL, et al.
Introduction of a composite parameter to the
pharmacokinetics of venlafaxine and its active
O-desmethyl metabolite. J Clin Pharmacol.
1992;32:716–724.
17. Preskorn SH, Kane CP, Lobello K, et al.
Cytochrome P450 2D6 phenoconversion is
common in patients being treated for
depression: implications for personalized
medicine. J Clin Psychiatry. 2013;74:614–621.
18. Amchin J, Zarycranski W, Taylor KP, et al.
Effect of venlafaxine on the pharmacokinetics
of risperidone. J Clin Pharmacol. 1999;39:
297–309.
19. Pearce RE, Cohen-Wolkowiez M, Sampson
MR, et al. The role of human cytochrome
p450 enzymes in the formation of
2-hydroxymetronidazole: CYP2A6 is the high
affinity (low km) catalyst. Drug Metab Dispos.
2013;41:1686–1694.
Olanzapine Long-Acting
Injections After Neuroleptic
Malignant Syndrome
Two Case Reports
To the Editors:
N euroleptic malignant syndrome (NMS)is a rare, unpredictable, but potentially
life-threatening condition associated with
antipsychotic use. It is characterized by ri-
gidity, tremor, fever, alterations of mental
status, leukocytosis, and creatine kinase
(CK) elevation.1 Although more than half
of all reported NMS cases are associated
with haloperidol, it is associated with© 2016 Wolters Kluwer Health, Inc. All rights reser
Copyright virtually all antipsychotics.2 Patients with
schizophrenia need to be treated after
recovery from NMS, but they are at an
elevated risk of developing NMS after fu-
ture exposure to antipsychotics. The data
regarding antipsychotic treatment after
NMS are sparse. Low-potency antipsy-
chotics are recommended, including cloza-
pine3 and quetiapine.1,3 Both drugs are
available only in oral formulations. Long-
acting injectable (LAI) antipsychotics are
recommended for nonadherent patients
with schizophrenia, and they showed supe-
riority compared with oral antipsychotics
in preventing hospitalizations.4 There are
no data of treatment with LAI antipsy-
chotics after the resolution of NMS, and
sustained high level of dopamine D2 recep-
tor occupancy might induce the recur-
rence of NMS. Olanzapine LAI was
associated with D2 receptor occupancy
of approximately 60%.5 Other LAI anti-
psychotics including haloperidol decanoate
and risperidone LAI6,7 occupy a higher per-
centage of dopamine D2 receptors. There
are currently no data for paliperidone and
aripiprazole LAIs.
Given that olanzapine was recom-
mended as a safe and effective option after
NMS8 and the relatively low occupancy of
dopamine D2 receptors with olanzapine
LAI,5 we present 2 patients, known to be
nonadherent with antipsychotics, whowere
treated with olanzapine LAI after the reso-
lution of NMS.
In both patients, diagnosis of schizo-
phrenia and NMS was established accord-
ing to criteria in the Diagnostic and
Statistical Manual of Mental Disorders,
Fourth Edition (published by the American
Psychiatric Press, 1994).CASE REPORTS
Case 1
A 30-year-old woman has been treated
for schizophrenia for 9 years. She had sev-
eral episodes of nonadherence to medica-
tion. For the last 3 years, she was receiving
risperidone LAI 50 mg twice monthly,
combined with oral risperidone 4 mg daily.
Because the patient was in good remission,
oral risperidone was withdrawn. Several
months before admission, she was receiv-
ing only risperidone LAI, twice monthly.
Despite regular applications, her condi-
tion worsened in terms of agitation, para-
noid delusions, insomnia, and disorganized
thinking and behavior, resulting in emer-
gency hospitalization. Upon admission,
short-acting muscular haloperidol was ap-
plied, followed by oral haloperidol 15 mg
daily for the next 9 days. For the next
6 days, haloperidol dose was reduced toved.
© 2016 Wolters Kluwer Health, Inc. All rights r6 mg daily, and risperidone was instituted
at the dose of 6 mg daily. The patient devel-
oped fever (highest temperature, 38.6°C),
muscular rigidity, tremor, elevated CK
levels (highest value, 3486 U/L; reference
range, 0–177 U/L), altered consciousness,
tachycardia (highest rate, 123), dysarthria,
and dysphagia. Antipsychotics were dis-
continued, and she was transferred to the
intensive care unit where she stayed for
2 weeks. Although fever resolved and CK
levels normalized, the patient developed
catatonia, presenting with negativism,
mutism, and occasional episodes of un-
controlled motor restlessness. She was
admitted in our department for electrocon-
vulsive therapy, where she received 12 ap-
plications and her condition improved. In
addition, oral olanzapine was started, with
slow and careful titration up to 20 mg daily.
Because treatment with olanzapinewas both
safe and effective and the risk of nonadher-
ence was high, olanzapine LAI 300 mg
twice monthly was instituted. The patient
has been receiving olanzapine LAI at the
same dose for 15months, with 10mg of oral
olanzapine twice daily and 1500 mg of
valproate to treat occasional mood swings.
Functional remission is achieved, and the
patient is working full time. Olanzapine
concentration was 323.1 nmol/L before LAI
injection and 251.0 nmol/L 3 hours after
the most recent injection (reference range,
64–256 nmol/L). However, the patient re-
ceived oral olanzapine at 7:00 AM, and the
first sample was taken at 1:00 PM. This cor-
responds to maximal concentration after
oral olanzapine intake.
Case 2
A 37-year-old man was given a diag-
nosis of schizophrenia 15 years ago and
had several episodes of nonadherence to
his treatment regimen. For the previous
7 years, he received the combination of ris-
peridone LAI 25 mg every 2 weeks and
clozapine 50 mg in the evening. He was
in remission for the last 6 years. However,
his condition worsened 2 weeks before ad-
mission, and the patient was given ari-
piprazole 10 mg daily. Ten days later, he
was hospitalized because of stupor, mut-
ism, and the loss of contact. Soon after,
he developed fever (highest temperature,
39.2°C), tremor, intensive perspiration, ele-
vated CK (highest value, 1473 U/L; refer-
ence range, 0–177 U/L), muscular rigidity,
tachycardia (highest value, 105), tachypnea,
leukocytosis (highest value, 15.2), inconti-
nence, and dehydration. He was treated in
the intensive care unit, and although somatic
symptoms were resolved during the next
4 days, the patient was still in stupor. He re-
ceived 11 applications of electroconvulsive
therapy. His condition gradually recovered,www.psychopharmacology.com 733
eserved.
